Last reviewed · How we verify

Haplo-HCT — Competitive Intelligence Brief

Haplo-HCT (Haplo-HCT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 3 Oncology Biologic Live · refreshed every 30 min

Target snapshot

Haplo-HCT (Haplo-HCT) — The First Affiliated Hospital of Soochow University. Haplo-HCT is a haploidentical hematopoietic cell transplantation approach that enables transplantation from half-matched donors by using post-transplant cyclophosphamide and other immunosuppressive strategies to prevent graft-versus-host disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Haplo-HCT TARGET Haplo-HCT The First Affiliated Hospital of Soochow University phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Haplo-HCT — Competitive Intelligence Brief. https://druglandscape.com/ci/haplo-hct. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: